Objective: Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment modality for a variety of malignant and non-malignant hematologic disorders. Myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) regimens could have different clinical outcomes. This purpose of this study was to assess the long-term outcome of MAC versus RIC regimens in patients with acute myeloid leukemia (AML) undergoing allogeneic HSCT. Materials and Methods: We retrospectively compared long-term outcomes with MAC and RIC regimens in patients with AML who underwent allo-HSCT at our tertiary transplantation center. Results: We analyzed survival outcomes after MAC-HSCT versus RICHSCT among 107 adult patients with AML diagnosed from 2001 through 2017. Of those, 44 patients underwent a MAC regimen, whereas 63 patients received a RIC regimen. The median follow-up time was 37 months (range: 6-210) for the entire group. The 3-year overall survival (OS) for RIC and MAC patients was 67% and 60%, respectively (p>0.05). The 3-year progression-free survival (PFS) for RIC and MAC patients was 88% and 77%. In multivariate analysis, the type of conditioning regimen (RIC vs. MAC) did not influence PFS (p=0.24). Acute graft-versus-host disease (GVHD) was seen in five of the RIC patients and 9 of the MAC patients. Chronic GVHD was seen in 16 of the RIC patients and 6 of the MAC patients. There was no significant difference between the two groups in terms of acute GVHD (p=0.089), but there was a significant difference between the two groups in terms of chronic GVHD (p=0.03). Conclusion: This retrospective analysis confirmed that MAC and RIC regimens had a consistently equivalent rate of OS and PFS in AML patients who underwent allo-HSCT. The choice of MAC versus RIC conditioning regimen might be decided on the basis of patient and disease characteristics.
Introduction Ankaferd hemostat (ABS; Ankaferd blood stopper, İstanbul, Turkey) is a folkloric medicinal plant extract. ABS has been conventionally used in Anatolia as a hemostatic agent for centuries (1). ABS contains a standardized combination of the plants Glycyrrhiza glabra, Thymus vulgaris, Alpinia officinarum, Vitis vinifera, and Urtica dioica. All of these plants have effects on the endothelium, the cellular components of blood, the development of new blood vessels, cell proliferation, and cell mediators (2,3). The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation (1). In addition to hemostatic functions, antiinflammatory (4), antiinfective (5), antifungal (6), and antioxidative (4) effects have been demonstrated for ABS. Thymus vulgaris has bacteriostatic activity for gram-positive and gram-negative bacteria (7-10). Likewise, Glycyrrhiza glabra, Vitis vinifera, and Alpinia officinarum have been shown to be antibacterial agents (11,12). Urtica dioica also has significant antibacterial activity against Streptococcus pyogenes, Staphylococcus aureus, and Staphylococcus epidermidis (12). ABS is currently licensed for numerous bleeding lesions of GIS pathologies, such as peptic ulcers (13), fundal varices (14), dieulafoy lesions (15,16), radiation colitis (17), rectal ulcers (18) and nonvariceal upper gastrointestinal bleeding (19). Most of the bleeding lesions were controlled with ABS in all patient groups (20-23). Furthermore, ABS is a potent hemostatic drug for controlling malignant gastrointestinal (GI) tumors. It has successful antineoplastic effects on colon cancer (as represented by the in vitro effects on CaCo-2 cells) (24). It significantly decreases tumor microvessel density (25). Almost 70% of gastric ulcer and 85% to 95% of duodenal ulcer patients have coexisting H. pylori infections (26,27). It is well recognized that H. pylori eradication therapy can reduce the repetition of peptic ulcer. Several different studies support the important role played by H. pylori in mucosa-associated lymphoid tissue (MALT) lymphomagenesis. Chronic infection with H. pylori is significantly related with the induction of gastric lymphoid Background/aim: Ankaferd hemostat (ABS; Ankaferd blood stopper, İstanbul, Turkey) is a folkloric medicinal plant extract. The aim of this study was to determine the effect of Ankaferd hemostat (ABS) on the fate of Helicobacter pylori strains. The study also aims to determine alterations in the antimicrobial resistance of three different H. pylori strains in response to ABS exposure. Materials and methods: H. pylori Strain 1 was obtained from the culture collection ATCC 43504 and passaged three times for viability. Strain 2 was isolated from a gastric ulcer patient and Strain 3 was isolated from a gastritis patient. 1% of ABS was added to all of the strains and antimicrobial susceptibility was observed on 30 and 60 min after application. Results: The efficacy of ABS solutions in achievi...
Serum biglycan might be used as a non-invasive marker of liver fibrosis. Further studies are needed to evaluate the usefulness of this marker.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.